VivoSim Labs stockholders approve reverse split range and equity plan increase
At its September 30, 2026 annual meeting, VivoSim Labs stockholders elected Keith Murphy and Adam Stern as Class III directors and approved a reverse stock split, at a ratio between 1-to-5 and 1-to-20 set by the Board, that can take effect until September 30, 2027. Stockholders also approved adding 3,165,000 shares to the equity incentive plan and approved issuing shares on warrant exercises and cutting the exercise price of 2024 warrants from $9.60 to $0.85, which may affect existing holders' ownership.
Key points
- Annual meeting held September 30, 2026; 6,180,635 shares, or 37.26% of 16,586,495 outstanding shares, were represented.
- Reverse stock split approved at a 1-to-5 to 1-to-20 ratio, to be set by the Board on or before September 30, 2027, with 74.12% of votes cast in favor.
- Equity incentive plan increase of 3,165,000 shares approved with 72.52% of votes cast in favor.
- Warrant approvals cover up to 4,705,883 shares and reduce the exercise price of May 13, 2024 warrants from $9.60 to $0.85 per share.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.